Business
ICU Medical manufactures infusion systems and other critical-care products.
ICU Medical contracted revenue, remained profitable, generated positive free cash flow at a 1.9% operating margin. Net income was near break-even and cash conversion weakened as capital spending, inventory and stock compensation rose.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 6.3%Watch
- Profitability — The company moved from a net loss of $117.688M to net income of $732KOK
- Cash flow — Free cash flow declined 26.4% to $91.804M from $124.66MWatch
- Margins — Operating margin expanded 12 bps to 1.92%OK
- Accounting — Net income was near break-even and cash conversion weakened as capital spending, inventory and stock compensation roseNote
- Insiders — 2 purchases and 6 salesOK
Where the revenue comes from
Fiscal 2025, as ICU MEDICAL INC/DE reports it. History and quarterly detail are in the app.
- Infusion Consumables$1.1B
- Infusion Systems$684.2M
- Vital Care$437.9M
Leadership changes
From ICU MEDICAL INC/DE's own filings, the day they're filed.
- Daniel Woolson · President · appointmenteff. 2024-09-30
- William Seeger · directors · departure
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-05-18
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ICU MEDICAL INC/DE, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.